Join
Live feed
·
PRReleasevia Quantisnow
Invivyd Inc. logo

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

ByQuantisnow·Wall Street's wire, on your screen.
IVVD· Invivyd Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IVVD (Invivyd Inc.) and more on Quantisnow.